VCaP, a cell-based model system of human prostate cancer.

Area of Science:

• Oncology
• Cell Biology
• Cancer Research

Background:

• Prostate cancer is a leading cause of cancer death in men.
• Metastatic prostate cancer, particularly hormone-refractory forms, presents significant treatment challenges.
• Existing cell line models may not fully recapitulate the characteristics of advanced or metastatic prostate cancer.

Purpose of the Study:

• To report the isolation and characterization of a novel prostate cancer cell line.
• To establish a cell line, VCaP (Vertebral-Cancer of the Prostate), derived from a vertebral metastatic lesion.
• To evaluate VCaP's suitability as a model for studying prostate cancer progression and metastasis.

Main Methods:

• Tissue acquisition from a vertebral metastatic lesion of a hormone-refractory prostate cancer patient.
• In vivo xenografting into SCID mice followed by in vitro culture.
• Characterization included soft agar cloning, in vivo/in vitro growth assays, karyotyping, immunocytochemistry (cytokeratin-18, PSA), RT-PCR (PAP), Western/Northern blots (Rb, p53), and androgen receptor assays.

Main Results:

• VCaP cells demonstrated in vitro immortality and in vivo serial passaging capability.
• The cell line expresses high levels of prostate specific antigen (PSA) and prostatic acid phosphatase (PAP).
• VCaP cells express cytokeratin-18, androgen receptor, and are sensitive to androgens both in vitro and in vivo.

Conclusions:

• VCaP is a novel prostate cancer cell line derived from a vertebral metastasis.
• It exhibits key characteristics of clinical prostate carcinoma, including PSA, PAP, and androgen receptor expression.
• VCaP serves as a valuable new model for advanced studies on prostate cancer progression and metastasis.